Fujifilm Manufacturing Drug Substances For New COVID-19 Antibody Test For Low- and Middle-Income Countries


Eli Lilly and Company of the United States is entrusted with the manufacture of drug substances for antibody drugs for the new coronavirus infection, which aims to spread to low- and middle-income countries.
FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (President: Kenji Sukeno), a contract development and manufacturing company (CDMO) * 2 for biopharmacy * 1 , is Eli Lilly. We are entrusted with the manufacture of API drugs for the new coronavirus infection (COVID-19) developed by and Company (hereinafter, Eli Lilly and Company). FDB will start manufacturing at its Danish base in April 2021 and will contribute to the spread of Eli Lilly’s antibody drugs for COVID-19 in low- and middle-income countries.

FDB is a biopharmacy CDMO with over 30 years of contract experience, advanced production technology and the latest equipment, and has developed a production process for all types of biopharmacy such as hormone preparations, antibody drugs, gene therapy drugs, and vaccines. We can handle from small-lot production to mass production, and contract manufacturing from drug substance to formulation / packaging. For this reason, the COVID-19 Treatment Promotion Project “COVID-19 Therapeutics Accelerator” (hereinafter “accelerator”) launched by the Bill & Melinda Gates Foundation together with the Wellcome Foundation and Mastercard in April this year * 3 Selected as a partner for the global supply of COVID-19 therapeutics to support development and manufacturing. We have secured a certain manufacturing capacity for our “accelerator” in our Danish base with mass production facilities.

Following an agreement between “Accelerator” and Eli Lilly to support the development and manufacture of an antibody drug for COVID-19 that the company is developing, FDB will manufacture the drug substance for the drug. It has been decided to accept the contract. From April 2021, FDB plans to start manufacturing the drug substance required for commercial production of antibody drugs for COVID-19 by Eli Lilly and Company at its Danish base.

FDB’s Danish base has mass production facilities such as six 20,000 liter animal cell culture tanks. Currently, we are working to further strengthen our contracting system by spending approximately 100 billion yen on the expansion of large culture tanks to double the production capacity of APIs, the establishment of new formulation lines, and the expansion of packaging lines.

As the development of COVID-19 vaccines and therapeutics progresses, FDB will promptly and globally supply high-quality biopharmacy that meets customer needs, and will contribute to controlling the spread of COVID-19 infection and ending the epidemic. I will continue.

* 1 Drugs that utilize biomolecules such as proteins, which have actions that cannot be achieved with small molecule drugs. In addition to insulin and growth hormone, it includes vaccines, antibody drugs, gene therapy drugs, etc.
* 2 Abbreviation for Contract Development & Manufacturing Organization. We provide a wide range of services to pharmaceutical companies, from cell line development in the early stages of drug development to production process development, stability testing, investigational drug development / manufacturing, and over-the-counter drug manufacturing.
* 3 A treatment promotion project that supports the rapid development and manufacture of therapeutic agents and vaccines for COVID-19.

Other Avigan/COVID-19/Fujifilm Biomedical Coverage ( 123456789,1011121314151617181920212223242526, 27)

Please don’t forget to follow us on FacebookTwitterInstagramYouTube

Plus our owners’ groups
Fujifilm GFX Owners Group
Fujifilm X-H Owners Group
Fujifilm X-T Owners Group
Fujifilm X-Pro Owners Group
Fujifilm X-E Owners Group
Fujifilm X-A Owners Group
Fujifilm X100 Owners Group

 

This entry was posted in Press releases and tagged , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.